See more : TC Energy Corporation (TRP) Income Statement Analysis – Financial Results
Complete financial analysis of Walvax Biotechnology Co., Ltd. (300142.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Walvax Biotechnology Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Healthia Limited (HLA.AX) Income Statement Analysis – Financial Results
- RTL Group S.A. (RGLXF) Income Statement Analysis – Financial Results
- Tasman Resources Ltd (TASEF) Income Statement Analysis – Financial Results
- Granite Real Estate Investment Trust (GRP-UN) Income Statement Analysis – Financial Results
- Physiomics Plc (PYC.L) Income Statement Analysis – Financial Results
Walvax Biotechnology Co., Ltd. (300142.SZ)
About Walvax Biotechnology Co., Ltd.
Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, researches and develops, produces, and sells bio-medicine products in China. The company offers biomedicines, such as vaccines, blood products, and others. It provides Group A, C meningococcal polysaccharide conjugate vaccine for infants below or equal to 2 years preventing diseases, such as cerebrospinal meningitis and septicemia; Group A and C meningococcal polysaccharide vaccine for in adults and children over the age of 2 years and adults to prevent disease caused by the bacterium Neisseria meningitidis group A or group C; and Group ACYW135 meningococcal polysaccharide vaccine for children above 2 years old to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis group A, C, Y, and W135. The company also offers haemophilus influenzae type b conjugate vaccine for children from the age of 2 months to 5 years for the prevention of infectious diseases, including meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis, etc. In addition, it provides diphtheria, tetanus, and acellular pertussis combined vaccine for the prevention of diphtheria, tetanus, and pertussis for individuals from the age of 3 months to 6 years; and 23-valent pneumococcal polysaccharide vaccine for children above 2 years old to prevent pneumococcal disease caused by 23 serotypes. Walvax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Kunming, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.11B | 5.09B | 3.46B | 2.94B | 1.12B | 879.04M | 668.26M | 591.00M | 1.01B | 719.02M | 583.09M | 537.56M | 473.81M | 358.79M | 239.13M | 184.06M | 129.36M |
| Cost of Revenue | 750.76M | 609.47M | 394.34M | 399.81M | 227.10M | 172.34M | 215.34M | 280.72M | 574.90M | 406.96M | 161.63M | 63.92M | 41.90M | 32.72M | 32.61M | 38.90M | 63.25M |
| Gross Profit | 3.36B | 4.48B | 3.07B | 2.54B | 894.12M | 706.70M | 452.92M | 310.29M | 431.12M | 312.07M | 421.46M | 473.64M | 431.91M | 326.07M | 206.52M | 145.16M | 66.11M |
| Gross Profit Ratio | 81.75% | 88.02% | 88.61% | 86.40% | 79.75% | 80.39% | 67.78% | 52.50% | 42.85% | 43.40% | 72.28% | 88.11% | 91.16% | 90.88% | 86.36% | 78.87% | 51.10% |
| Research & Development | 776.43M | 932.89M | 621.49M | 176.49M | 64.81M | 125.48M | 99.01M | 107.99M | 136.35M | 96.36M | 27.45M | 28.90M | 33.55M | 18.52M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 99.56M | 100.09M | 159.94M | 134.85M | 119.99M | 54.08M | 23.48M | 38.94M | 147.74M | 76.07M | 49.22M | 27.38M | 17.13M | 13.67M | 31.87M | 29.28M | 30.19M |
| Selling & Marketing | 1.47B | 2.03B | 1.33B | 1.13B | 499.13M | 349.46M | 253.68M | 150.37M | 208.17M | 187.47M | 104.34M | 122.70M | 144.18M | 91.60M | 61.11M | 70.57M | 26.27M |
| SG&A | 1.87B | 2.13B | 1.49B | 1.27B | 619.11M | 403.54M | 277.16M | 189.31M | 355.92M | 263.54M | 153.55M | 150.08M | 161.31M | 105.27M | 92.97M | 99.85M | 56.46M |
| Other Expenses | 104.15M | 86.58M | 89.58M | 76.31M | 46.01M | -61.78M | -432.51M | 195.41M | 19.17M | 11.81M | 6.83M | -17.58M | -28.76M | 13.58M | 5.09M | 12.28M | 5.01M |
| Operating Expenses | 2.75B | 3.15B | 2.20B | 1.52B | 729.94M | 601.69M | 431.80M | 407.12M | 588.59M | 502.22M | 343.99M | 232.48M | 225.22M | 146.84M | 95.23M | 102.43M | 58.51M |
| Cost & Expenses | 3.50B | 3.75B | 2.60B | 1.92B | 957.04M | 774.03M | 647.15M | 687.84M | 1.16B | 909.18M | 505.62M | 296.40M | 267.11M | 179.56M | 127.85M | 141.33M | 121.76M |
| Interest Income | 74.23M | 70.03M | 45.42M | 37.43M | 36.96M | 22.95M | 13.35M | 16.63M | 6.53M | 18.64M | 24.19M | 41.20M | 43.54M | 1.36M | 367.15K | 210.28K | 121.78K |
| Interest Expense | 3.81M | 7.11M | 5.77M | 597.49K | 30.56M | 39.79M | 115.59M | 137.10M | 153.05M | 170.62M | 70.18M | 9.97M | 3.16M | 4.82M | 2.48M | 3.88M | 1.08M |
| Depreciation & Amortization | 317.23M | 275.50M | 149.55M | 128.40M | 82.22M | 127.06M | 126.17M | 122.21M | 73.12M | 117.36M | 126.33M | 38.36M | 15.56M | 11.27M | 12.42M | 10.38M | 3.11M |
| EBITDA | 938.23M | 1.35B | 865.90M | 1.50B | 341.88M | 1.34B | -341.68M | 288.35M | -642.30M | 440.18M | 206.81M | 330.32M | 265.20M | 199.28M | 109.11M | 53.43M | 11.58M |
| EBITDA Ratio | 22.81% | 32.43% | 32.09% | 40.12% | 24.74% | 156.58% | -40.38% | 49.44% | -5.14% | 71.72% | 40.23% | 62.19% | 58.51% | 56.10% | 48.62% | 33.17% | 11.27% |
| Operating Income | 613.97M | 1.10B | 967.53M | 1.06B | 232.88M | 1.25B | -144.15M | -160.36M | -898.16M | 128.16M | 3.51M | 253.89M | 237.98M | 173.42M | 89.17M | 35.16M | 5.55M |
| Operating Income Ratio | 14.92% | 21.62% | 27.94% | 35.90% | 20.77% | 141.66% | -21.57% | -27.13% | -89.28% | 17.82% | 0.60% | 47.23% | 50.23% | 48.33% | 37.29% | 19.10% | 4.29% |
| Total Other Income/Expenses | -14.99M | -28.97M | -1.33M | 318.22M | -3.42M | 1.04B | -432.53M | 175.65M | 13.48M | 15.27M | 6.79M | 13.57M | 7.93M | 9.77M | -9.98M | 8.15M | 3.91M |
| Income Before Tax | 598.98M | 1.07B | 708.95M | 1.37B | 229.46M | 1.18B | -576.66M | 34.68M | -884.68M | 137.96M | 10.30M | 267.47M | 245.91M | 183.19M | 94.20M | 43.31M | 9.46M |
| Income Before Tax Ratio | 14.56% | 21.05% | 20.47% | 46.73% | 20.47% | 134.63% | -86.29% | 5.87% | -87.94% | 19.19% | 1.77% | 49.76% | 51.90% | 51.06% | 39.39% | 23.53% | 7.31% |
| Income Tax Expense | 87.65M | 132.24M | 107.59M | 162.12M | 35.33M | 120.81M | -18.42M | 4.66M | 39.97M | 41.25M | 5.42M | 42.11M | 38.37M | 28.77M | 17.87M | 8.61M | 2.03M |
| Net Income | 419.39M | 728.65M | 601.35M | 1.00B | 194.14M | 1.05B | -537.14M | 70.46M | -840.90M | 143.42M | 47.89M | 232.80M | 207.54M | 154.42M | 76.33M | 34.70M | 7.42M |
| Net Income Ratio | 10.19% | 14.33% | 17.37% | 34.13% | 17.31% | 119.02% | -80.38% | 11.92% | -83.59% | 19.95% | 8.21% | 43.31% | 43.80% | 43.04% | 31.92% | 18.85% | 5.74% |
| EPS | 0.26 | 0.46 | 0.38 | 0.65 | 0.13 | 0.68 | -0.35 | 0.05 | -0.60 | 0.10 | 0.03 | 0.17 | 0.15 | 0.14 | 0.07 | 0.05 | 0.08 |
| EPS Diluted | 0.26 | 0.45 | 0.38 | 0.65 | 0.13 | 0.68 | -0.35 | 0.05 | -0.60 | 0.10 | 0.03 | 0.17 | 0.15 | 0.14 | 0.07 | 0.05 | 0.08 |
| Weighted Avg Shares Out | 1.60B | 1.60B | 1.60B | 1.55B | 1.54B | 1.54B | 1.54B | 1.41B | 1.40B | 1.43B | 1.44B | 1.41B | 1.41B | 1.08B | 1.05B | 632.71M | 93.91M |
| Weighted Avg Shares Out (Dil) | 1.60B | 1.60B | 1.60B | 1.55B | 1.54B | 1.54B | 1.54B | 1.41B | 1.40B | 1.43B | 1.44B | 1.41B | 1.41B | 1.08B | 1.05B | 632.71M | 93.91M |
Source: https://incomestatements.info
Category: Stock Reports